Daiwa Securities Group
NGM

Daiwa Securities Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Daiwa Securities Group’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-265
Closed – – 1412
2023
Q3 		$0 Hold
265
– – ﹤0.01% 1351
2023
Q2 		$1K Hold
265
– – ﹤0.01% 1313
2023
Q1 		$1K Hold
265
– – ﹤0.01% 1296
2022
Q4 		$1K Hold
265
– – ﹤0.01% 1304
2022
Q3 		$3K Hold
265
– – ﹤0.01% 1210
2022
Q2 		$3K Hold
265
– – ﹤0.01% 1214
2022
Q1 		$4K Hold
265
– – ﹤0.01% 1203
2021
Q4 		$5K Hold
265
– – ﹤0.01% 1207
2021
Q3 		$6K Buy
265
+119
+82% +$2.62K ﹤0.01% 1172
2021
Q2 		$3K Hold
146
– – ﹤0.01% 1124
2021
Q1 		$4K Buy
146
+16
+12% +$448 ﹤0.01% 1095
2020
Q4 		$4K Sell
130
-246
-65% -$5.38K ﹤0.01% 1077
2020
Q3 		$6K Hold
376
– – ﹤0.01% 1081
2020
Q2 		$5K Hold
376
– – ﹤0.01% 1111
2020
Q1 		$5K Hold
376
– – ﹤0.01% 1106
2019
Q4 		$7K Buy
+376
New +$5.5K ﹤0.01% 1091

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Daiwa Securities Group's NGM Position: Q4 2023 in Review

Daiwa Securities Group sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2023, closing a stake of 265 shares.

Daiwa Securities Group first reported a position in NGM in Q4 2019 and held it in 16 quarters. The position peaked at $7K in Q4 2019. 83 funds tracked by Wall St. Rank hold NGM as of Q4 2023.

  • Daiwa Securities Group reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Daiwa Securities Group sold 265 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2023.
  • Daiwa Securities Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 16 quarters.
  • Daiwa Securities Group's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $7K in Q4 2019.
  • 83 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2023.

Based on Daiwa Securities Group's 13F filing for Q4 2023, filed 31 Jan 2024.